PAREXEL International Corporation (NASDAQ:PRXL) issued its quarterly earnings data on Monday. The medical research company reported $1.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.94 by $0.08, RTT News reports. PAREXEL International Corporation had a net margin of 5.12% and a return on equity of 28.68%. During the same quarter in the prior year, the business posted $0.94 earnings per share.

Shares of PAREXEL International Corporation (NASDAQ PRXL) opened at 87.75 on Tuesday. The firm has a 50-day moving average of $87.51 and a 200 day moving average of $75.37. The stock has a market cap of $4.45 billion, a PE ratio of 38.57 and a beta of 0.79. PAREXEL International Corporation has a 52 week low of $51.16 and a 52 week high of $87.86.

COPYRIGHT VIOLATION NOTICE: This article was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.watchlistnews.com/parexel-international-corporation-prxl-announces-quarterly-earnings-results-beats-expectations-by-0-08-eps/1529197.html.

A number of brokerages have recently issued reports on PRXL. Zacks Investment Research downgraded shares of PAREXEL International Corporation from a “buy” rating to a “hold” rating in a research report on Thursday, August 17th. Barclays PLC downgraded shares of PAREXEL International Corporation from an “overweighr” rating to an “equal weight” rating and set a $87.00 price objective for the company. in a research report on Tuesday, June 20th. Credit Suisse Group reissued a “neutral” rating and set a $83.00 price objective (up previously from $65.00) on shares of PAREXEL International Corporation in a research report on Tuesday, June 6th. Raymond James Financial, Inc. raised shares of PAREXEL International Corporation from an “underperform” rating to a “mkt perform” rating in a research report on Tuesday, June 20th. Finally, Goldman Sachs Group, Inc. (The) raised shares of PAREXEL International Corporation from a “sell” rating to a “neutral” rating and boosted their price objective for the company from $63.00 to $77.00 in a research report on Tuesday, May 23rd. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $75.93.

Large investors have recently made changes to their positions in the stock. Public Employees Retirement System of Ohio increased its stake in shares of PAREXEL International Corporation by 4.5% in the first quarter. Public Employees Retirement System of Ohio now owns 1,713 shares of the medical research company’s stock valued at $108,000 after buying an additional 73 shares during the period. Meadow Creek Investment Management LLC increased its stake in shares of PAREXEL International Corporation by 7.1% in the first quarter. Meadow Creek Investment Management LLC now owns 1,980 shares of the medical research company’s stock valued at $125,000 after buying an additional 132 shares during the period. Invictus RG purchased a new stake in shares of PAREXEL International Corporation during the first quarter valued at $158,000. Glen Harbor Capital Management LLC increased its stake in shares of PAREXEL International Corporation by 7.1% in the first quarter. Glen Harbor Capital Management LLC now owns 2,520 shares of the medical research company’s stock valued at $159,000 after buying an additional 168 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of PAREXEL International Corporation by 10.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,986 shares of the medical research company’s stock valued at $173,000 after buying an additional 180 shares during the period. 87.49% of the stock is owned by institutional investors.

PAREXEL International Corporation Company Profile

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Earnings History for PAREXEL International Corporation (NASDAQ:PRXL)

Receive News & Ratings for PAREXEL International Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.